PDF DatasheetHuman, Mouse, and Rat Anti-Cytokeratin Antibody Product Attributes
Species: Human, Mouse, and Rat
Tested Applications: Flow Cytometry, Immunofluorescence, Western Blot, Immunohistochemistry (IHC).
Application Notes: Flow Cytometry (0.5-1ug of antibody/million cells in 0.1ml), Immunofluorescence (0.5-1.0ug of antibody/ml), Western Blot (0.5-1.0ug of antibody/ml), Immunohistochemistry (IHC) (Formalin-fixed) (0.25-0.5ug of antibody/ml for 30 min at RT)
Clonality: Monoclonal
Anti-Cytokeratin Antibody Clone: 34BE12
Clone 34BE12 Host and Isotype: Mouse IgG1 kappa
Anti-Human, Mouse, and Rat Cytokeratin Positive Control Sample: PC12 cells, Skin, Prostate carcinoma
Cellular Localization of Antibody <34BE12 Staining: Cytoplasmic
Buffer and Stabilizer: 10mM PBS with 0.05% BSA & 0.05% azide.
Antibody Concentration: 200ug/ml
Antibody Purification Method:Protein A/G Purified
Immunogen: Solubilized keratin extract from human stratum corneum
Storage Conditions: Store at 2 to 8° C (refrigerate). Stable for 24 months when properly stored.
Cytokeratin Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in Cytokeratin antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. Low, but measureable presence of Cytokeratin could be seen in. We were unable to detect Cytokeratin in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Cytokeratin expression as measured by anti-Cytokeratin antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | + | – | – | + | + | – | + | + | – | – | – | + | + | – | – | – | – | – | + | – |
| KRT76 Variability | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ |
| Cytokeratin General Information | |
|---|---|
| Alternate Names | |
| KRT2B, KRT2P, HUMCYT2A, Keratin, type II Cytoskeletal 2 oral, K76, Keratin 2p (K2P), Keratin-76, Cytokeratin-2P (CK-2P, Type-II Keratin Kb9, anti-KRT2B antibody, anti-KRT2P antibody, anti-HUMCYT2A antibody, anti-Keratin antibody, anti-type II Cytoskeletal 2 oral antibody, anti-K76 antibody, anti-Keratin 2p (K2P) antibody, anti-Keratin-76 antibody, anti-Cytokeratin-2P (CK-2P antibody, anti-Type-II Keratin Kb9 antibody | |
| Molecular Weight | |
| 50-67kDa | |
| Chromosomal Location | |
| 12q13.13 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | KRT76 |
| Entrez Gene ID | 51350 |
| Ensemble Gene ID | ENSG00000185069 |
| RefSeq Protein Accession(s) | NP_056932 |
| RefSeq mRNA Accession(s) | NM_015848, |
| RefSeq Genomic Accession(s) | NG_012420, NC_000012, NC_018923 |
| UniProt ID(s) | Q01546 |
| UniGene ID(s) | Q01546 |
| HGNC ID(s) | 24430 |
| Cosmic ID(s) | KRT76 |
| KEGG Gene ID(s) | hsa:51350 |
| PharmGKB ID(s) | PA147357785 |
| General Description of Cytokeratin. | |
| This antibody recognizes CK1, CK5, CK10, CK14. In normal epithelia, it stains stratified epithelia, myoepithelial cells, basal cells in the prostate gland, bronchi. This MAb shows no reactivity with hepatocytes, pancreatic acinar cells, proximal renal tubules, or endometrial glands; there is no reactivity with cells derived from simple epithelia. Mesenchymal tumors, lymphomas, melanomas, neural tumors,, neuroendocrine tumors are negative with this antibody. It stains myoepithelial cells, has been shown to be useful in distinguishing prostate adenocarcinoma from benign prostate. This antibody has also been useful in separating benign from malignant intraductal breast proliferations. | |
Limitations and Warranty
enQuire Bio’s Cytokeratin, Basic Anti-Human Monoclonal is available for Research Use Only. This antibody is guaranteed to work for a period of two years when properly stored.
There are no reviews yet.